Peter Körtvélyessy

1.9k total citations
21 papers, 829 citations indexed

About

Peter Körtvélyessy is a scholar working on Neurology, Molecular Biology and Physiology. According to data from OpenAlex, Peter Körtvélyessy has authored 21 papers receiving a total of 829 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Neurology, 5 papers in Molecular Biology and 5 papers in Physiology. Recurrent topics in Peter Körtvélyessy's work include Amyotrophic Lateral Sclerosis Research (9 papers), Peripheral Neuropathies and Disorders (7 papers) and Autoimmune Neurological Disorders and Treatments (6 papers). Peter Körtvélyessy is often cited by papers focused on Amyotrophic Lateral Sclerosis Research (9 papers), Peripheral Neuropathies and Disorders (7 papers) and Autoimmune Neurological Disorders and Treatments (6 papers). Peter Körtvélyessy collaborates with scholars based in Germany, Austria and Netherlands. Peter Körtvélyessy's co-authors include Frank Leypoldt, Klaus‐Peter Wandinger, Mar Petit‐Pedrol, Maarten J. Titulaer, Eric Lancaster, Peter A.E. Sillevis Smitt, Helena Ariño, Agnes van Sonderen, Francesc Graus and Paul W. Wirtz and has published in prestigious journals such as SHILAP Revista de lepidopterología, Neurology and Scientific Reports.

In The Last Decade

Peter Körtvélyessy

20 papers receiving 822 citations

Peers

Peter Körtvélyessy
Mike Sabbagh Canada
Makoto Hirotani Japan
Yusuke Fujioka Japan
Toshika Ohkawa Japan
Friedmar R. Kreuz Germany
Mac Robinson United States
Gaëlle Cavillon France
Elisabet O. Sjöström Sweden
Daniela Sinske Germany
Tadashi Kanouchi Japan
Mike Sabbagh Canada
Peter Körtvélyessy
Citations per year, relative to Peter Körtvélyessy Peter Körtvélyessy (= 1×) peers Mike Sabbagh

Countries citing papers authored by Peter Körtvélyessy

Since Specialization
Citations

This map shows the geographic impact of Peter Körtvélyessy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Körtvélyessy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Körtvélyessy more than expected).

Fields of papers citing papers by Peter Körtvélyessy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Körtvélyessy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Körtvélyessy. The network helps show where Peter Körtvélyessy may publish in the future.

Co-authorship network of co-authors of Peter Körtvélyessy

This figure shows the co-authorship network connecting the top 25 collaborators of Peter Körtvélyessy. A scholar is included among the top collaborators of Peter Körtvélyessy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Peter Körtvélyessy. Peter Körtvélyessy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bernsen, Sarah, et al.. (2025). Serum Cardiac Troponin T Levels as a Therapy Response Marker in Tofersen‐Treated ALS. Muscle & Nerve. 72(3). 509–514. 2 indexed citations
2.
3.
Fillmer, Ariane, Semiha Aydın, Bernd Ittermann, et al.. (2024). Plasma p‐tau181 and GFAP reflect 7T MR‐derived changes in Alzheimer's disease: A longitudinal study of structural and functional MRI and MRS. Alzheimer s & Dementia. 20(12). 8684–8699. 6 indexed citations
4.
Weishaupt, Jochen H., Peter Körtvélyessy, Ute Weyen, et al.. (2024). Tofersen decreases neurofilament levels supporting the pathogenesis of the SOD1 p.D91A variant in amyotrophic lateral sclerosis patients. SHILAP Revista de lepidopterología. 4(1). 150–150. 11 indexed citations
5.
Meyer, Thomas, Patrick Weydt, Susanne Petri, et al.. (2023). Neurofilament light‐chain response during therapy with antisense oligonucleotide tofersen in SOD1‐related ALS: Treatment experience in clinical practice. Muscle & Nerve. 67(6). 515–521. 53 indexed citations
6.
Appeltshauser, Luise, Peter Körtvélyessy, Klaus‐Peter Wandinger, et al.. (2020). Antiparanodal antibodies and IgG subclasses in acute autoimmune neuropathy. Neurology Neuroimmunology & Neuroinflammation. 7(5). 33 indexed citations
7.
Vural, Atay, Luise Appeltshauser, Christian Dresel, et al.. (2019). Anti–pan-neurofascin IgG3 as a marker of fulminant autoimmune neuropathy. Neurology Neuroimmunology & Neuroinflammation. 6(5). 56 indexed citations
8.
Koch, Henner, Cristina Elena Niturad, Stephan Theiss, et al.. (2019). In vitro neuronal network activity as a new functional diagnostic system to detect effects of Cerebrospinal fluid from autoimmune encephalitis patients. Scientific Reports. 9(1). 5591–5591. 7 indexed citations
9.
Pawlitzki, Marc, Leoni Rolfes, Hans‐Jochen Heinze, et al.. (2019). Transient MOG antibody seroconversion associated with immunomodulating therapy. Multiple Sclerosis and Related Disorders. 37. 101420–101420. 3 indexed citations
10.
Körtvélyessy, Peter, H.-J. Heinze, Johannes Prudlo, & Daniel Bittner. (2018). CSF Biomarkers of Neurodegeneration in Progressive Non-fluent Aphasia and Other Forms of Frontotemporal Dementia: Clues for Pathomechanisms?. Frontiers in Neurology. 9. 504–504. 27 indexed citations
11.
Pawlitzki, Marc, Stefanie Schreiber, Daniel Bittner, et al.. (2018). CSF Neurofilament Light Chain Levels in Primary Progressive MS: Signs of Axonal Neurodegeneration. Frontiers in Neurology. 9. 1037–1037. 28 indexed citations
12.
Raoof, Rana, Eva M. Jiménez‐Mateos, Sebastian Bauer, et al.. (2017). Cerebrospinal fluid microRNAs are potential biomarkers of temporal lobe epilepsy and status epilepticus. Scientific Reports. 7(1). 3328–3328. 94 indexed citations
13.
Jiménez‐Mateos, Eva M., Rana Raoof, David Boyle, et al.. (2017). “TORNADO” – Theranostic One-Step RNA Detector; microfluidic disc for the direct detection of microRNA-134 in plasma and cerebrospinal fluid. Scientific Reports. 7(1). 1750–1750. 55 indexed citations
14.
Körtvélyessy, Peter, et al.. (2017). Progranulin and Its Related MicroRNAs after Status Epilepticus: Possible Mechanisms of Neuroprotection. International Journal of Molecular Sciences. 18(3). 490–490. 8 indexed citations
15.
Schreiber, Stefanie, Grażyna Dębska–Vielhaber, Susanne Abdulla, et al.. (2017). Peripheral nerve atrophy together with higher cerebrospinal fluid progranulin indicate axonal damage in amyotrophic lateral sclerosis. Muscle & Nerve. 57(2). 273–278. 18 indexed citations
16.
Sonderen, Agnes van, Helena Ariño, Mar Petit‐Pedrol, et al.. (2016). The Clinical Spectrum of Caspr2-Antibody Associated Disease (S12.008). Neurology. 86(16_supplement). 2 indexed citations
17.
Sonderen, Agnes van, Helena Ariño, Mar Petit‐Pedrol, et al.. (2016). The clinical spectrum of Caspr2 antibody–associated disease. Neurology. 87(5). 521–528. 277 indexed citations
18.
Körtvélyessy, Peter, et al.. (2015). Progranulin levels in status epilepticus as a marker of neuronal recovery and neuroprotection. Epilepsy & Behavior. 49. 170–172. 11 indexed citations
19.
Körtvélyessy, Peter, Jan Bauer, Christian Michael Stoppel, et al.. (2015). Complement-associated neuronal loss in a patient with CASPR2 antibody–associated encephalitis. Neurology Neuroimmunology & Neuroinflammation. 2(2). e75–e75. 50 indexed citations
20.
Körtvélyessy, Peter, et al.. (2015). Progranulin and Amyloid-β Levels: Relationship to Neuropsychology in Frontotemporal and Alzheimer’s Disease. Journal of Alzheimer s Disease. 46(2). 375–380. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mike Sabbagh Breakdown of academic impact, for papers by Makoto Hirotani Breakdown of academic impact, for papers by Yusuke Fujioka Breakdown of academic impact, for papers by Toshika Ohkawa Breakdown of academic impact, for papers by Friedmar R. Kreuz Breakdown of academic impact, for papers by Mac Robinson Breakdown of academic impact, for papers by Gaëlle Cavillon Breakdown of academic impact, for papers by Elisabet O. Sjöström Breakdown of academic impact, for papers by Daniela Sinske Breakdown of academic impact, for papers by Tadashi Kanouchi
Rankless by CCL
2026